Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Santini D, et al. Among authors: venditti o. Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Ann Oncol. 2012. PMID: 22396447 Free article. Clinical Trial.
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Santini D, et al. Among authors: venditti o. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6. doi: 10.1158/1078-0432.CCR-07-0551. Clin Cancer Res. 2007. PMID: 17671133
Cetuximab: from bench to bedside.
Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Vincenzi B, et al. Among authors: venditti o. Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241. Curr Cancer Drug Targets. 2010. PMID: 20088790 Review.
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Among authors: venditti o. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.
'Old' and 'new' drugs for the treatment of cancer pain.
Santini D, Lanzetta G, Dell'Aquila E, Vincenzi B, Venditti O, Russano M, Papapietro N, Denaro V, Tonini G, Ripamonti C. Santini D, et al. Among authors: venditti o. Expert Opin Pharmacother. 2013 Mar;14(4):425-33. doi: 10.1517/14656566.2013.774375. Expert Opin Pharmacother. 2013. PMID: 23438421 Review.
Pazopanib and pancreatic toxicity: a case report.
Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D. Russano M, et al. Among authors: venditti o. BMC Res Notes. 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4. BMC Res Notes. 2015. PMID: 25967382 Free PMC article.
29 results